Physician profile
Jon M Grudem
NPI 1477649531
$293,353.18
in general payments reported to CMS, 2019-2025
21 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $53K · 2021: $80K · 2022: $32K · 2023: $35K · 2024: $41K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Travel and Lodging: $7,612 · Food and Beverage: $3,623 · Consulting Fee: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,687.50 |
| Travel and Lodging | $7,612.06 |
| Food and Beverage | $3,622.57 |
| Consulting Fee | $1,525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $152,052.65 | 2021-2025 | |
| Allergan, INC. | $104,248.54 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $15,848.01 | 2021 | |
| Pfizer INC. | $10,896.57 | 2023-2025 | |
| Lundbeck LLC | $5,192.17 | 2020-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $4,152.20 | 2022 | |
| Argenx US, INC. | $176.55 | 2023-2025 | Vyvgart |
| Lilly USA, LLC | $146.22 | 2019-2024 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $108.19 | 2020-2025 | Austedo Xr, Austedo Xr |
| Merz Pharmaceuticals, LLC | $97.80 | 2025 | Xeomin |
| Amgen INC. | $61.42 | 2022-2023 | Aimovig |
| Sk Life Science, INC. | $59.55 | 2023-2024 | |
| Impel Pharmaceuticals INC. | $48.92 | 2022-2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $47.73 | 2023-2025 | Ultomiris |
| Ge Healthcare | $42.64 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $41.05 | 2022-2023 | Rytary |
| Acadia Pharmaceuticals INC | $40.38 | 2023-2025 | Nuplazid |
| Inspire Medical Systems, INC. | $29.88 | 2025 | Inspire |
| Eisai INC. | $24.86 | 2025 | |
| Springworks Therapeutics, INC. | $22.41 | 2025 | Gomekli |
| Ucb, INC. | $15.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Grudem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.